Defendant
5 cases as defendant.
Apotex Corp. is the U.S. subsidiary of Apotex Inc., a Canadian-based global pharmaceutical company. Apotex Inc. was founded in 1974 and is headquartered in Toronto, Ontario, Canada. Apotex Corp.'s U.S. operations are headquartered in Weston, Florida. The broader entity, Apotex Health Corp., completed an Initial Public Offering (IPO) on the Toronto Stock Exchange (TSX) in June 2026, trading under the symbol APTX. Prior to the IPO, Apotex Pharmaceutical Holdings Inc. was acquired by SK Capital Partners LP, a U.S. private equity firm, in April 2023. As of 2023-2025, Apotex Inc. employs approximately 6,200 to 8,000 people worldwide. Apotex Health Corp. reported a trailing 12-month revenue of $2.53 billion as of March 31, 2026, and its market capitalization was approximately $4.92 billion as of June 19, 2026.
Apotex specializes in the development, manufacturing, and distribution of generic and branded pharmaceuticals, biosimilars, and active pharmaceutical ingredients (APIs). Their extensive product portfolio includes over 300 generic drugs across various therapeutic areas such as cardiovascular, anti-infectives, gastrointestinal, central nervous system, mental health, and pain management, which are exported to more than 115 countries. The company also has dedicated divisions like Apobiologix for biosimilar development and ApoPharma for innovative medicines.
In terms of patent litigation, Apotex Corp. operates as an operating company that primarily defends against patent infringement claims. The provided data indicates one tracked case where Apotex Corp. is a defendant and zero cases where it is a plaintiff. This posture is consistent with a generic drug manufacturer that often challenges originator drug patents to bring more affordable generic versions to market.
A notable case for Apotex Corp. within the tracked data is its role as a defendant in Merck v. Apotex Inc. et al. Apotex has a history of engaging in significant patent litigation, frequently challenging patent validity or arguing non-infringement against brand-name pharmaceutical companies. Examples include past disputes with Janssen over Apo-Macitentan, Sanofi-Synthelabo regarding Plavix, AstraZeneca concerning a generic version of Crestor, Takeda over an Entyvio biosimilar, and Horizon concerning a generic version of Pennsaid 2%.
Original complaint asserted '919; plaintiffs ceased asserting the '919 patent against all defendants. The consolidated case was later globally stayed pending IPR appeals on the '947 and '903 patents.
Action asserting the '708 patent; resolved by settlement/consent judgment.
Hatch-Waxman ANDA litigation. The '427 was expressly named among the patents-in-suit, but Celgene withdrew its '427 infringement claims. Consolidated/coordinated for claim construction with 17-cv-03159. Case terminated 2021-08-19.
The court entered judgment entirely in favor of Apotex, declaring claims 17, 19, 20, and 22–27 of the '903 patent (among others) invalid as obvious and dismissing all of Merck's infringement claims.
Consolidated into 22-1365 (except trial). The '919 patent was asserted in the original complaint but dropped; Apotex's ANDA was approved Nov. 24, 2025. The consolidated case involved the '947 and '903 patents.